{"protocolSection":{"identificationModule":{"nctId":"NCT02643784","orgStudyIdInfo":{"id":"ESR-14-10028"},"organization":{"fullName":"RenJi Hospital","class":"OTHER"},"briefTitle":"Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke","officialTitle":"Exploratory Study on the Effects of Early Rosuvastatin Treatment in Patients With Acute Ischemic Stroke","acronym":"AIS"},"statusModule":{"statusVerifiedDate":"2015-12","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-12"},"primaryCompletionDateStruct":{"date":"2017-07","type":"ESTIMATED"},"completionDateStruct":{"date":"2017-07","type":"ESTIMATED"},"studyFirstSubmitDate":"2015-12-16","studyFirstSubmitQcDate":"2015-12-28","studyFirstPostDateStruct":{"date":"2015-12-31","type":"ESTIMATED"},"lastUpdateSubmitDate":"2015-12-28","lastUpdatePostDateStruct":{"date":"2015-12-31","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"RenJi Hospital","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is an exploratory, randomized, open-label, 2-arm, parallel-group study exploring the efficacy of rosuvastatin (20mg/day) in patients with acute ischemic stroke.","detailedDescription":"This is a 90-day, explanatory; randomized; open-label, 2-arm; parallel group with blinded outcome evaluation study exploring the efficacy and study of early rosuvastatin 20 mg/d treatment in acute ischemic patients with stroke onset in 24 hours."},"conditionsModule":{"conditions":["Ischemic"],"keywords":["acute ischemic stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":100,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Rosuvastatin","type":"EXPERIMENTAL","description":"Rosuvastatin study drug will be supplied in tablets (10 mg), assigned dose to be taken orally, once daily by subjects randomized to receive rosuvastatin 20 mg(take rosuvastatin until 14th day).","interventionNames":["Drug: Rosuvastatin","Other: Control"]},{"label":"Control","type":"NO_INTERVENTION","description":"Control group(don't take rosuvastatin until 14th day), as directed by the study physician."}],"interventions":[{"type":"DRUG","name":"Rosuvastatin","description":"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.\n\nFollow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.","armGroupLabels":["Rosuvastatin"],"otherNames":["RSV"]},{"type":"OTHER","name":"Control","description":"Randomized Treatment Period (Day 1 through Day 14):\n\nNo treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day.","armGroupLabels":["Rosuvastatin"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percent changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke","timeFrame":"0-14d"}],"secondaryOutcomes":[{"measure":"Absolute changes in infarction volumes measured by MRI on the 14th day compared with the baseline of the stroke","timeFrame":"0-14d"},{"measure":"Proportion of patients whose infarction volume reduced on the 14th day compared with the baseline of the stroke","timeFrame":"0-14d"},{"measure":"The neurological outcomes measured by NIHSS (14,90 days), compared between statin group and standard group","timeFrame":"14-90d"},{"measure":"The functional outcome measured by modified Rankin Scale (14,90 days), compared between statin group and standard group","timeFrame":"14-90d"},{"measure":"The rate of the new-onset infarct assessed by MRI from baseline to 14th day, compared between statin group and standard group","timeFrame":"0-14d"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. 45 to 75 years old patients;\n2. Stroke involving the vascular territory of the middle cerebral artery (MCA) as judged by clinical and MRI evidences;\n3. Time from symptom onset to take the study assigned medication is within 24 hours;\n4. Statin naïve or discontinued at least 3 month before stroke onset;\n5. First ever stroke or mild sequelae (with modified Rankin Score 0-1) before the index event;\n6. Moderate neurological deficit with baseline NIHSS scoring from 4-20;\n7. MRI scans （T1W1、T2W2、T2Flair、DWI、SWI）accomplished from 12 to 48 hours after the onset;\n8. Consent form signed.\n\nExclusion Criteria:\n\n-\n\nAny of the following is regarded as a criterion for exclusion from the study:\n\n1. Stroke involving the vascular territory of the vertebrobasilar artery as judged by clinical and MRI evidences;\n2. Hemorrhagic transformation or intracranial hemorrhage on baseline MRI. MRI performed between 12-48 hours after the onset, if MRI provides evidences which met with the exclusion criteria, the patients will be excluded from the study;\n3. Any circumstances under which MRI scans can't be performed;\n4. Evidences suggesting cardiogenic stroke such as atrial fibrillation, acute coronary syndrome, patent foramen ovale , etc;\n5. Comatose with NIHSS 1a\\>1;\n6. Medical or psychiatric conditions such as severe hepatic or renal dysfunction, heart failure, malignancy, major depression, dementia, alcohol or drug abuse;\n7. Suitable for rt-Plasminogen Activator thrombolysis treatment;\n8. Receiving medication with possible neuroprotective functions after stroke onset;\n9. Currently take steroids therapy;\n10. Diagnosed with malignancy within 5 years;\n11. Patients with myopathy or serum creatine kinase \\> 3 times the upper limit of normal not caused by myocardial injury;\n12. Severe renal function damage (eGFR\\<30);\n13. Concurrent use ciclosporin;\n14. A history of hypersensitivity of statins and other severe complication;\n15. Child-bearing women ;\n16. Patients who are or may be pregnant;\n17. Other conditions under which patients not pertinent to attend the study as judged by the investigators.","healthyVolunteers":false,"sex":"ALL","minimumAge":"45 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"ipdSharingStatementModule":{"ipdSharing":"YES"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068718","term":"Rosuvastatin Calcium"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000057847","term":"Lipid Regulating Agents"},{"id":"D000019161","term":"Hydroxymethylglutaryl-CoA Reductase Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"}],"browseLeaves":[{"id":"M298","name":"Rosuvastatin Calcium","asFound":"Movement","relevance":"HIGH"},{"id":"M5071","name":"Calcium","relevance":"LOW"},{"id":"M5088","name":"Calcium, Dietary","relevance":"LOW"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"BDCA","name":"Bone Density Conservation Agents"}]}},"hasResults":false}